Slovenian drug maker Krka's Q1 cons net profit rises 5% y/y

LJUBLJANA (Slovenia), May 20 (SeeNews) - Slovenian pharmaceuticals producer Krka [LJE:KRKG] has said its consolidated net profit rose 5% year-on-year to 90.7 million euro ($96.1 million) in the first quarter of 2022.
Krka's consolidated sales increased 9% on the year to 432.5 billion euro in the three months through March, the company said in an interim financial statement filed with the Ljubljana Stock Exchange.
Krka's consolidated earnings before interest, tax, depreciation and amortisation (EBITDA) amounted to 133.6 million euro in the first three months, up 8% year-on-year.
The Krka Group allocated 22.7 million euro to investments in January-March, of which 14.8 million euro to the controlling company.
The group employed 11,631 people at the end of March, up from 11,511 at the end of 2021.
Krka's shares closed down 0.23% to 87.80 euro on the Ljubljana bourse on Thursday.
($ = 0.94423 euro)
המשך לקרוא
היכנס או הירשם לחשבון TradingView בחינם, ותיהנה מגישה פתוחה לחדשות פיננסים גלובליות, בזמן אמת.